162 related articles for article (PubMed ID: 36015203)
21. Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters.
Riekes MK; Dereymaker A; Berben P; Augustijns P; Stulzer HK; Van den Mooter G
Int J Pharm; 2017 Mar; 520(1-2):49-58. PubMed ID: 28153650
[TBL] [Abstract][Full Text] [Related]
22. Enteric coated magnetic HPMC capsules evaluated in human gastrointestinal tract by AC biosusceptometry.
Corá LA; Romeiro FG; Paixão FC; Américo MF; Oliveira RB; Baffa O; Miranda JR
Pharm Res; 2006 Aug; 23(8):1809-16. PubMed ID: 16858651
[TBL] [Abstract][Full Text] [Related]
23. In vitro release characteristics of hard shell capsule products coated with aqueous- and organic-based enteric polymers.
Murthy KS; Kubert DA; Fawzi MB
J Biomater Appl; 1988 Jul; 3(1):52-79. PubMed ID: 3199314
[TBL] [Abstract][Full Text] [Related]
24. Preparation of the traditional Chinese medicine compound recipe heart-protecting musk pH-dependent gradient-release pellets.
Song H; Guo T; Zhang R; Zheng C; Ma Y; Li X; Bi K; Tang X
Drug Dev Ind Pharm; 2002 Nov; 28(10):1261-73. PubMed ID: 12476872
[TBL] [Abstract][Full Text] [Related]
25. Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles.
Bussemer T; Bodmeier R
Int J Pharm; 2003 Nov; 267(1-2):59-68. PubMed ID: 14602384
[TBL] [Abstract][Full Text] [Related]
26. Enteric-coating of pulsatile-release HPC capsules prepared by injection molding.
Macchi E; Zema L; Maroni A; Gazzaniga A; Felton LA
Eur J Pharm Sci; 2015 Apr; 70():1-11. PubMed ID: 25585355
[TBL] [Abstract][Full Text] [Related]
27. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.
Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW
Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647
[TBL] [Abstract][Full Text] [Related]
28. Improvement in the disintegration of shellac-coated soft gelatin capsules in simulated intestinal fluid.
Pearnchob N; Dashevsky A; Bodmeier R
J Control Release; 2004 Feb; 94(2-3):313-21. PubMed ID: 14744483
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Capsule-in-Capsule Combinations on In Vivo Disintegration in Human Volunteers: A Combined Imaging and Salivary Tracer Study.
Rump A; Weiss FN; Schulz L; Kromrey ML; Scheuch E; Tzvetkov MV; White T; Durkee S; Judge KW; Jannin V; Bellamine A; Weitschies W; Grimm M
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959284
[TBL] [Abstract][Full Text] [Related]
30. A novel concept in enteric coating: a double-coating system providing rapid drug release in the proximal small intestine.
Liu F; Lizio R; Meier C; Petereit HU; Blakey P; Basit AW
J Control Release; 2009 Jan; 133(2):119-24. PubMed ID: 18930772
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a food-based enteric coating for capsules and its compatibility with an alternative sealing method.
Caillard R; Blais JS; Akinocho G; Jacques W
Int J Pharm; 2016 Feb; 499(1-2):321-329. PubMed ID: 26773598
[TBL] [Abstract][Full Text] [Related]
32. Formulation and evaluation of enteric coated tablets of proton pump inhibitor.
Nair AB; Gupta R; Kumria R; Jacob S; Attimarad M
J Basic Clin Pharm; 2010 Sep; 1(4):215-21. PubMed ID: 24825991
[TBL] [Abstract][Full Text] [Related]
33. Influence of capsule shell composition on the performance indicators of hypromellose capsule in comparison to hard gelatin capsules.
Al-Tabakha MM; Arida AI; Fahelelbom KM; Sadek B; Saeed DA; Abu Jarad RA; Jawadi J
Drug Dev Ind Pharm; 2015; 41(10):1726-37. PubMed ID: 25586554
[TBL] [Abstract][Full Text] [Related]
34. The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules.
Pavloff N; Hauser TA; Williams C; Isbell SL; Cadieux B; Johnson M
Drug Des Devel Ther; 2018; 12():2795-2804. PubMed ID: 30233142
[TBL] [Abstract][Full Text] [Related]
35. SEM/EDX and confocal microscopy analysis of novel and conventional enteric-coated systems.
Liu F; Lizio R; Schneider UJ; Petereit HU; Blakey P; Basit AW
Int J Pharm; 2009 Mar; 369(1-2):72-8. PubMed ID: 19061944
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Evaluation of a Gastro-Resistant HPMC-Based "Next Generation Enteric" Capsule.
Rump A; Kromrey ML; Scheuch E; Jannin V; Rehenbrock L; Tzvetkov MV; Weitschies W; Grimm M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297435
[TBL] [Abstract][Full Text] [Related]
37. Design, Preparation, and Evaluation of Enteric Coating Formulation of HPMC and Eudragit L100 on Carboxylated Agarose Hydrogel by Using Drug Tartrazine.
Khan MJ; Huang WC; Akhlaq M; Raza S; Hamadou AH; Yuning G; Sun J; Mao X
Biomed Res Int; 2022; 2022():1042253. PubMed ID: 35127935
[TBL] [Abstract][Full Text] [Related]
38. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
Varum FJ; Hatton GB; Freire AC; Basit AW
Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
[TBL] [Abstract][Full Text] [Related]
39. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD).
Leopold CS; Eikeler D
J Drug Target; 1998; 6(2):85-94. PubMed ID: 9886233
[TBL] [Abstract][Full Text] [Related]
40. 3D printing and enteric coating of a hollow capsular device with controlled drug release characteristics prepared using extruded Eudragit® filaments.
Choudhury D; Murty US; Banerjee S
Pharm Dev Technol; 2021 Nov; 26(9):1010-1020. PubMed ID: 34412566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
